Concepedia

Author

Natalia Tovar

Consorci Institut D'Investigacions Biomediques August Pi I SunyerORCID

Also Known As

Leili Behrooz, N Tovar, N. Tovar, Natalia Tovar

243

Publications

1.6K

Citations

24

H-Index

35

Concepts

All Affiliations

Consorci Institut D'Investigacions Biomediques August Pi I SunyerUniversitat de BarcelonaHospital Clínic de BarcelonaInstituto de Investigación Biomédica de SalamancaThe University of Texas MD Anderson Cancer Center
NT

About

Natalia Tovar is an author at Consorci Institut D'Investigacions Biomediques August Pi I Sunyer specializing in medicine, pathology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

428

2

Immunology

8

8

311

3

Health Sciences

4

4

119

4

Cell Biology

2

2

62

5

Cellular Therapies

2

2

91

Natalia Tovar

×

34

Publications

1.3K

Citations

24

H-Index

YearCitations

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka,

Blood

2021

98

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, Jordi Esteve, Kimmo Porkka,

Blood

2019

85

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas,

The Lancet Oncology

2023

76

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Nico Gagelmann, Danai Dima, Maximilian Merz,

Journal of Clinical Oncology

2024

70

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka,

Blood

2020

68

Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Carlos Fernández de Larrea, Alfons Navarro, Rut Tejero,

Clinical Cancer Research

2012

65

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression

Carlos Fernández de Larrea, Ignacio Isola, Arturo Pereira,

Leukemia

2018

63

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution

Natalia Tovar, Carlos Fernández de Larrea, Juan I. Aróstegui,

Haematologica

2013

55

Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents

Carlos Fernández de Larrea, Natalia Tovar, M. a. T. Cibeira,

Haematologica

2010

51

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in <i>in vitro</i> and <i>in vivo</i> models of multiple myeloma by blockade of Ikaros and MYC signaling

Tania Díaz, Vanina Rodríguez, Ester Lozano,

Haematologica

2017

50

Page 1